Turkey erythrocyte membranes showed specific binding of [3Hlepinephrine. Knowledge about cell receptors for hormones and neurotransmitters has mostly been obtained indirectly by study of the responses of tissues to the active agents. To date, none of the hormone receptors residing in cell membranes has been defined in molecular terms. However, recent information has been obtained about the specific binding of ACTH (1), glucagon (2), acetylcholine (3, 4), and insulin (5) It seemed to us of particular importance to study the binding of the catecholamines, epinephrine and norepinephrine, to the receptor for the following reasons. The catecholamine receptors are ubiquitous, being present in almost every cell type of a mammal. The catecholamines act not only as humoral hormones, but also as neurotransmitters in the brain and in other nerve cells. There are at least two types of receptors for catecholamines, a-and 3-, defined on the basis of responses in the intact cell; the nature of the difference between these two receptors at the molecular level is unknown.
structure. Epinephrine binding was inhibited by the fiadrenergic blocking agent propranolol, which also inhibited the activation of adenylate cyclase by the hormone. The specificity of plienethylamine derivatives in displacing [3H1epinephrine from the binding sites showed that a typical catecholamine receptor was responsible for the binding. Displacement of the bound hormone by analogs lacking the catechol group was more extensive at 370C than at 0'C. Some of the analogs that displaced epinephrine from the binding site caused only a feeble activation of the adenylate cyclase, but were able to inhibit the activation of the enzyme by epinephrine. Thus, binding to a catecholamine receptor on a membrane preparation is an essential, but insufficient, condition to elicit a response.
Knowledge about cell receptors for hormones and neurotransmitters has mostly been obtained indirectly by study of the responses of tissues to the active agents. To date, none of the hormone receptors residing in cell membranes has been defined in molecular terms. However, recent information has been obtained about the specific binding of ACTH (1), glucagon (2) , acetylcholine (3, 4) , and insulin (5) to membrane preparations containing the respective receptors for these hormones. In the work with ACTH by Lefkowitz et al. (1) , and particularly in the extensive studies with glucagon by Rodbell et al. (2) , convincing evidence was obtained that binding indeed occurred at the true, functional receptor, i.e., the preparation retained the hormone-responsive adenylate cyclase.
It seemed to us of particular importance to study the binding of the catecholamines, epinephrine and norepinephrine, to the receptor for the following reasons. The catecholamine receptors are ubiquitous, being present in almost every cell type of a mammal. The catecholamines act not only as humoral hormones, but also as neurotransmitters in the brain and in other nerve cells. There are at least two types of receptors for catecholamines, a-and 3-, defined on the basis of responses in the intact cell; the nature of the difference between these two receptors at the molecular level is unknown.
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The Preceptor activates, and appears to be part of, the adenylate cyclase system (6) . Its mechanism of action can, therefore, be studied in a cell-free membrane preparation. The relative specificity of the catecholamine receptor with respect to different hormone derivatives varies widely from tissue to tissue for unknown reasons (7) . An almost inexhaustible collection of catecholamine derivatives is available to test the function of each chemical group of the hormone molecule in the binding reaction and in the activation that results from such binding.
There are major obstacles that render the study of catecholamine binding to its receptor quite difficult. Hormones of this group have a relatively low affinity for the receptor, and readily dissociate from it during washing (8, 9) . They undergo spontaneous oxidation at alkaline pH, are taken up for storage at nerve endings, and are readily metabolized by most tissues (10) . There have been, therefore, few attempts to study attachment of the hormone to the receptor. Binding of labeled epinephrine to liver plasma membranes has been reported (11) . The pH optimum for binding was 10.5, and the bound radioactivity was not released by 5% trichloroacetic acid.
No evidence was presented to show that the radioactivity bound was epinephrine. Very recently, binding of norephinephrine to heart microsomes was reported to have the specificity of a d-receptor (12) . However, there was no information on whether the fraction studied contained the hormone-responsive adenylate cyclase, or how much of the bound radioactivity was unchanged norepinephrine. Previous work on heart microsomes by other investigators had demonstrated that much of the bound material after incubation with [3H]-norepinephrine was composed of products of the monoamine oxidase (EC 1.4.3.4) reaction and other reactions (13) .
For the present study, turkey erythrocyte membranes were chosen since Qye and Sutherland showed an epinephrineresponsive adenylate cyclase in this system (14) . The cellular purity, the ease of preparation of cell membranes, the absence of nerve endings that take up epinephrine, and the probable paucity of the usually potent enzymes that metabolize epinephrine appeared to offer great advantages for the erythrocyte system in the study of the catecholamine receptor. This communication reports on the specificity of the receptor for the binding of sympathomimetic amines and activation of the adenylate cyclase. amines were purchased from Sigma Chemical Co. and K and K(U.S.A.) arnd from Biotec (Sweden).
Turkey erythrocyte membranes (ghosts) were prepared according to 0ye and Sutherland (14) . Adenylate cyclase assays were performed in triplicate by the procedure of Krishna and Brodie (15), with miflor modifications (9) . There was only a trace of enzyme activity in the absence of epinephrine or fluoride. Activation by the hormone was measured as pmoles of cAMP formed when epinephrine was present in the reaction mixture. Activation by a hormone analog was measured similarly, by substituting it for the hormone. Some hormone analogs, when present in the reaction mixture, [3H]epinephrine, 1 mM unlabeled epinephrine was run through the same procedure and was used to calculate the amount of unbound radioactivity that had been trapped in the pellet (16) . It was calculated that 45% of the total extracted radioactivity was actually bound (315 pmol of epinephrine bound per mg of membrane protein). An additional tube was run through the entire procedure without erythrocyte membranes, and was the control for subsequent chromatography. Aliquots were analyzed by thin layer chromatography on cellulose powder in two solvents: n-butyl alcohol-acetic acid-water 60:15:25 (as used by New Englahd Nuclear Co.) and phenol-water 90:10 (17) . The chromatograms were cut into strips of 0.5-cm each and counted. The recovery of counts in the 0.5-cm strips, relative to the amount placed at the origin, was 91% with phenol-water and 103% with butanol-acetic acid-water. The results obtained with the latter solvent are shown. It is evident that the radioactivity extracted from the membranes is concentrated in the peak. Essentially the same findings were obtained with phenolwater. t Activity was tested at 0.1 mM, and is expressed relative to the activity of 0.1 mM epinephrine. The activity of epinephrine at 1 mM was the same as that at 0.1 mM. the receptor; therefore, experiments were usually performed at 1-10MAM of epinephrine. In order to define the nature of the binding, and in view of the relative instability of epinephrine under oxygen in cell-free extracts, we analyzed the bound radioactive material. About 99% of the radioactivity was readily eluted from the membranes by 0.1 N acetic acid. When the eluted radioactivity was analyzed by thin layer chromatography in two solvents, only one peak, which corresponded in its mobility to epinephrine, was observed (Fig.  3) . Some radioactive contaminants present in the stock of original ['H]epinephrine were not bound to the membranes. The recovery of radioactivity on the chromatograms was 90-100%; therefore, the hormone structure remained intact during the binding reaction.
When the membrane preparation was heated 1 min at 98°C at pH 6.8, the binding was completely inactivated. The dependence of activity on pH varied somewhat with the buffer and the temperature. The binding activity did not change much in the pH range from 6.8 to 8.5, but dropped to almost zero at pH 6.0. A test at pH higher than 8.5 is probably not meaningful, because of the instability of epinephrine (10). 0.2 mM p-Hydroxymercuribenzoate had no inhibitory effect on epinephrine binding, but inhibited the adenylate cyclase 66 and 43% when the enzyme was activated by 10 mM of fluoride and 0.1 mM of epinephrine, respectively. Thus, the sensitivity of adenylate cyclase to sulfhydryl reagents (9, 14, 18) is probably inherent in the catalytic unit and not in the hormone receptor.
It seemed crucial to establish whether the hormone was indeed bound to a functional catecholamine receptor. Two criteria were used to examine this problem: (a) Specificity of various hormone analogs as inhibitors of [3H]epinephrine binding; (b) Specificity of the hormone analogs as activators of adenylate cyclase, and also as inhibitors of enzyme activation by epinephrine. We assumed that the effect of a hormone analog was a measure of its specific binding to the receptor. also caused a steep decline in affinity. These findings are in excellent agreement with the well-known specificity of the catecholamine receptors in animal systems (7, 10) . No less important was the finding that the specificity of activation of the adenylate cyclase by hormone analogs was similar to the specificity of binding. However, dopamine, which showed a high binding affinity, demonstrated a relatively low adenylate cyclase activation, confirming the importance of the /3-hydroxyl for the activation process (7) . Some additional observations in Table 1 are noteworthy. Interference with binding caused by the carboxyl group in DOPA is partially overcome either by esterification, as in DOPA methyl ester, or by addition of a ,3-hydroxyl, as in DOPS (see Table 1 ). Thus, the ,3-hydroxyl can have a contributory function in the binding process that was not evident from comparison of dopamine with epinephrine and norepinephrine. While DOPA methyl ester, DOPS, and serotonin at relatively high concentrations showed some affinity for the binding site, these compounds activated the adenylate cyclase poorly or not at all (Table 1) . It is, of course, possible that a compound binds to the receptor that controls adenylate -Proc. Nat. Acad. Sci. USA 69 (1972) Epinephrine concentration was 10 AM throughout. The enzyme activity at 10 AM was about 25% lower than that shown in Table 1 at 0.1 mM. All other conditions were as in Table 1 . In assays containing only epinephrine, the binding activity at 370C was either the same as at 00C or 30% lower, depending on the membrane batch.
cyclase activity, but fails to induce the change required for enzyme activation. In this case, the compound may compete with a true activator for the receptor, and may thus inhibit adenylate cyclase activation. Table 2 demonstrates that a number of compounds inhibit the activation of adenylate cyclase caused by epinephrine. Since adenylate cyclase was measured at 370C0 inhibition of [3H]epinephrine binding was tested at 370C, as well as at 00C. Inhibition of binding at 370C is roughly equivalent to the inhibition of the epinephrine-activated adenylate cyclase in the case of ephedrine, phenylephrine, metanephrine, and serotonin. Dopamine and DOPS by themselves stimulate the adenylate cyclase to some extent (Table 1) and are, therefore, not expected to inhibit the enzyme drastically in the presence of epinephrine. DOPA methyl ester inhibited adenylate cyclase activation by epinephrine, but its effect on binding seemed to be more powerful (Table 2) .
Propranolol, a specific p3-receptor-blocking agent, caused complete inhibition of the adenylate cyclase when only part of the binding was blocked. Phentolamine, an a-receptor blocking agent, did not inhibit binding when tested at 0.02 mM. At this concentration, it specifically and completely inhibited the a-receptor in rat parotid gland (19) . The effect of phentolamine at the higher concentration is probably nonspecific. It is also evident from Table 2 that several compounds inhibit epinephrine more effectively at 370C than at 00C. This characteristic appears to be typical of those derivatives that do not possess the catechol structure, the top three compounds in Table 2 .
DISCUSSION
We used several criteria to ascertain that the binding measured indeed occurs between the hormone and the biologically relevant catecholamine recej)tor. The bound radioactivity was extracted and analyzed to establish that it was unchanged el)lnephrine. The specificity of binding of hormone analogs and derivatives was examined to establish whether it fits the gross biological specificity of the catecholaminie receptor, as found in other systems (7, 10) . Finally, the specificity of hormone binding and of adenylate cyclase activation were compared with each other in the same membrane l)reparation.
The findings support the conclusion that the binding sites measured and characterized indeed belong to a typical catecholamine receptor. The specificity pattern of the binding reaction was quite different from that of the known enzymes involved in the synthesis and breakdown of epinel)hrine (10) , and it is therefore unlikely that these enzymes could have contributed significantly to the binding.
In comparison of the effect of a hormone analog on the binding reaction with its effect on adenylate cyclase activation, it must be remembered that the two processes are measured under different assay conditions. It is, therefore, surprising that the data for binding and enzyme activation show, in most cases, a better fit than can be expected on the basis of the above qualifications. However, the f3-adrenergic blocking agent, propranolol, seemed to inhibit the adenylate cyclase activation more extensively than it inhibited the binding of the hormone. One possible explanation is that when propranolol occupies only part of the receptor sites, it prevents activation of the adenylate cyclase at neighboring sites that are still occupied by epinephrine.
Half-maximal binding occurred at 30 /iM epinephrine, which was equivalent to the Km for activation of the adenylate cyclase in the erythrocyte membrane. This value is somewhat higher than the Km reported for the fat cell (20) and parotid gland (9) enzymes. It must be emphasized that many of the physiologically important adenylate cyclases, such as those of heart (8), liver (8) , and brain (21) , become saturated by the catecholamine only at a concentration of 0.1 mM or higher. Therefore, in this respect also, there is no essential difference between the turkey erythrocyte and other catecholamine-responsive systems. It seems reasonable to expect that the findings on the catecholamine receptor of the turkey erythrocyte membrane will be relevant to the action of this receptor in other tissues. 
